Piper Sandler raised the firm’s price target on Century Therapeutics (IPSC) to $4 from $2 and keeps an Overweight rating on the shares. The firm notes Century plans to submit an IND for CNTY-813 this year and report initial data in 2027. Piper estimates Century now hold pro forma cash of about $267M to fund operations into Q1 2029.
Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IPSC:
- Century Therapeutics Highlights Progress in Immune-Evasive Cell Therapies
- Century Therapeutics price target lowered to $6.60 from $8 at Clear Street
- Century Therapeutics Announces Oversubscribed $135 Million Financing
- Century Therapeutics prices 117.4M shares at $1.15 in private placement
- Century Therapeutics announces resignation of board member